AgingResearch.NewsJoin free

mRNA-1345

mRNA-1345 has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest story, Oct 23, 2026: “Respiratory syncytial virus vaccine prompted lasting T cell responses”.

Intervention

1 paper studies it1 findingUpdated

“mRNA-1345 induced comparable CD4+ and CD8+ T cell responses in both cohorts, with CD4+ responses persisting for 24 months.”
The mRNA-based RSV vaccine mRNA-1345 induces robust and durable CD4⁺ T cell responses against RSV in younger and older adultsScience advances2026doi:10.1126/sciadv.aeh4436

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • 1 of 1 finding with company ties
  • Human trial1

What did studies of mRNA-1345 find?

1

Studies of mRNA-1345 measured 1 outcome; the most studied are T cell responses (1 study).

T cell responses

upin humans1

1 study

  1. mRNA-1345 induces T cell responses in humans.

    “mRNA-1345 induced comparable CD4+ and CD8+ T cell responses in both cohorts, with CD4+ responses persisting for 24 months.”

    Human trialmRNA vaccine24 months

    Respiratory syncytial virus vaccine prompted lasting T cell responses

    Science advances

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 11 paper in 12 months
Science Advances

Respiratory syncytial virus vaccine prompted lasting T cell responses

Helper T cell responses persisted for 24 months after vaccination, with comparable responses in younger and older adults.Helper T cell responses persisted for 24 months after vaccination, with comparable responses in younger and older adults.

Non-randomized trial in peopleLung
Paper

Related